ALHC vs. TEVA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and TEVA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
TEVA stands out with 18.96 billion USD in market value—about 6.25× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to TEVA’s calmer 0.63, suggesting both higher upside and downside potential.
TEVA is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALHC, which is purely domestic.
| Symbol | ALHC | TEVA |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Teva Pharmaceutical Industries Limited |
| Country | US | IL |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. John E. Kao | Mr. Richard D. Francis |
| Price | 15.33 USD | 16.55 USD |
| Market Cap | 3.03 billion USD | 18.96 billion USD |
| Beta | 1.33 | 0.63 |
| Exchange | NASDAQ | NYSE |
| IPO Date | March 26, 2021 | February 16, 1982 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALHC and TEVA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and TEVA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ALHC nor TEVA turned a profit—both carry negative P/E ratios of -32.75 and -14.61, underscoring continued losses that pressure their valuations.
- Analysts assign negative forward PEG ratios to both ALHC (-1.11) and TEVA (-1.13), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
| Symbol | ALHC | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | -14.61 |
| Forward PEG Ratio (TTM) | -1.11 | -1.13 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 1.14 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 3.00 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 24.73 |
| EV-to-EBITDA (TTM) | -64.47 | 23.01 |
| EV-to-Sales (TTM) | 0.86 | 2.06 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 44.66 |
Dividend Comparison
Neither ALHC nor TEVA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALHC | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and TEVA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- TEVA posts a quick ratio of 0.74, indicating limited coverage of short-term debts from its most liquid assets—while ALHC at 1.69 enjoys stronger liquidity resilience.
- ALHC posts a negative interest coverage ratio (-2.98), reflecting an operating loss. TEVA, with its ratio at 0.44, also faces difficulty, as its operating earnings do not cover its interest expenses.
| Symbol | ALHC | TEVA |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 1.03 |
| Quick Ratio (TTM) | 1.69 | 0.74 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 2.71 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.44 |
| Interest Coverage Ratio (TTM) | -2.98 | 0.44 |